Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.
about
Timing and extent of response in colorectal cancer: critical review of current data and implication for future trialsRole of positron emission tomography for the monitoring of response to therapy in breast cancerIncorporating clinical trial data into daily cancer care.Response criteria for glioma.Validation of novel imaging methodologies for use as cancer clinical trial end-pointsBrain Radiotherapy plus Concurrent Temozolomide versus Radiotherapy Alone for Patients with Brain Metastases: A Meta-Analysis.Metabolic burden measured by (18)f-fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in patients with small cell lung cancerCancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.Fool's gold, lost treasures, and the randomized clinical trial.Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?Letrozole in advanced breast cancer: the PO25 trial.Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancerRelationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer.Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerProgression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.Is Participation in Cancer Phase I Trials Really Therapeutic?Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?Surrogacy of tumor response and progression-free survival for overall survival in metastatic breast cancer resistant to both anthracyclines and taxanes.Assessing the outcomes of HIV-infected persons receiving treatment for Kaposi sarcoma in Conakry-Guinea.Immune gene expression and response to chemotherapy in advanced breast cancer.Trends in endpoint selection in clinical trials of advanced breast cancer.Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer.Biosimilars as a strategy to improve sustainability.
P2860
Q26797292-E2689F28-E1B1-4B9F-9622-0A059853BFD1Q28080621-6C3DB7D1-142F-4094-A10B-2F82488763B2Q30836868-4ACA426D-8E77-431F-B576-CE05F510A366Q31172444-68007716-B44D-4F15-9FA4-C5A0B240419FQ33394106-58E9A0E5-B4D9-43A4-82F6-FA53D379C827Q33430404-DF272CEB-BF92-4B74-BCDB-62C19CE888E0Q33619243-5FD91FE5-AD51-4F40-B889-F7CB3032E49EQ34023973-A4869C95-45A6-4208-87F3-F48585A3A5E3Q34669260-24460CBD-2A12-45C7-8661-CCEF3116833EQ35507680-FACB3A48-CC06-48B7-AA83-6263D10ADE76Q35820247-17AA892E-547F-4458-9EB1-17071748828BQ36026424-DBE61651-9BD9-4777-AF10-ED652326BE6AQ36349459-494E6454-908A-4ECD-95A3-225BCD831560Q36589778-E8BEA72A-1019-43E8-AFDF-3394C2087A31Q36671882-DA4E9A9B-646C-4628-B69A-8F8224E674B2Q36977501-CFA9B8C1-B1F6-40BE-AE6A-3899F6441A70Q37393234-D5B32EDC-5F7C-473E-8129-0EDE1AB2FC83Q37630084-11C5AE89-6D17-455D-8CE2-98302F40DE15Q37660474-B64088B5-A6C2-48E2-BFFC-6705BAE75FD1Q38737416-5D056DBA-2AE8-4E51-B5AB-C35D17ED94B7Q38839151-FA295ECE-2849-42AA-A3D2-04100158EB60Q40025547-2BA21036-2E72-447D-86EC-B0E8DE7B758DQ44789980-4CA502E5-DCF8-4FB2-97B3-578BA85E0101Q47094434-2B0B0D37-DF4C-4838-85A1-023AFAF5FFEEQ49689455-E5C23C5C-4625-4FF5-B5F7-7674006D3218Q50160426-9152F168-B9E2-45F9-B393-338698CA0EAFQ52692689-E1A7C69F-0644-4ACD-9750-29ED41F9C188Q53195496-3AACBF88-925A-46F6-B944-C2ABCEE37409Q54974112-B1710DC6-2F11-46A2-8475-973538611FC9
P2860
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Objective response to chemothe ...... static breast cancer patients.
@en
Objective response to chemothe ...... static breast cancer patients.
@nl
type
label
Objective response to chemothe ...... static breast cancer patients.
@en
Objective response to chemothe ...... static breast cancer patients.
@nl
prefLabel
Objective response to chemothe ...... static breast cancer patients.
@en
Objective response to chemothe ...... static breast cancer patients.
@nl
P2093
P50
P356
P1476
Objective response to chemothe ...... static breast cancer patients.
@en
P2093
Christian Focan
James Paul
Marco Danova
Marco Venturini
Maria P Sormani
Riccardo Rosso
P304
P356
10.1200/JCO.2005.02.106
P407
P577
2005-06-13T00:00:00Z